Intracervical Vasopressin
Intracervical Vasopressin for Completion of Hysteroscopic Removal of Retained Products of Conception
Prisma Health-Upstate
50 participants
Oct 30, 2025
INTERVENTIONAL
Conditions
Summary
This randomized study looks at whether using a medicine injected into the cervix of the uterus (intracervical), called vasopressin, helps to achieve better removal of retained products of conception (RPOC). RPOC means that after a pregnancy has ended (through miscarriage, abortion, or delivery), some parts of the pregnancy tissue, usually from the placenta or fetus, have stayed in the uterus. A hysteroscopic removal of RPOC is one type of treatment. This is a surgical procedure where a doctor uses a small camera attached to a thin tube (called a hysteroscope) to look inside the uterus. The main goal of the study is : • To add to the existing research through this study to see if the injection of intracervical vasopressin leads to improved completion rates of hysteroscopic management of RPOC. Participants will: • would be randomized to receive either vasopressin intracervical injection or a placebo injection (non-active saline) during your procedure. Information from the procedure will be collected from the participant's medical record.
Eligibility
Inclusion Criteria3
- Women
- Aged 18-51
- Undergoing surgical management for retained products of conception, postpartum retained products of conception or 1st trimester missed or incomplete abortion
Exclusion Criteria5
- Hemodynamic instability
- Active hemorrhage- soaking pad/hour
- Allergy to vasopressin
- Concern for intrauterine arteriovenous malformation
- Inability to consent
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Intracervical injection of Vasopressin
Intracervical Injection of saline
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07102615